1@@24152Dulaglutide: a new drug for the treatment of type 2 diabetesDONG Xian-hong, ZHU Jiang, MA Shuai2281-2283,23113Siltuximab: a novel IL-6 monoclone antibody drug for the treatment of muticentric castleman diseaseZHANG Yu-qin, DU Xiao-li2284-2287,23294Analysis of the situation of clinical trials for antitumor drugs supported by foreign pharmaceutical industries in ChinaCHENG Xian-kui, WU Zhi-ang2288-2294,23235Research on the patent operation of transnational corporations based on vaccines for cervical cancer Gardasil and CervarixWANG Jing, WEI Jun, FENG Xiao-liang, WANG Chao, WEI Wei2295-23006Application scope of drug test data protection under TRIPS and the legislative choice of ChinaYANG Li, ZHANG Da-wei, CHEN Jing, LIN Lin2301-2307,23357Introduction of the drafting procedure of "Guidelines on Development and Evaluation of Biosimilars (drafting)"BAI Yu, WANG Hai-xue, XIE Song-mei, GAO Chen-yan, YIN Hong-zhang, LUO Jian-hui2308-23118Analysis of N-linked glycan profile of human/murine chimeric anti-CD20 antibodies by capillary electrophoresis2312-2316,23459Optimization and application of HUVEC proliferation inhibitory assay2317-232310Recent progress in researches for action mechanism of adjuvantsLIU Yi-bo, GENG Xing-chao, WANG Ju-feng, LI Bo2324-232911Preclinical safety similarity evaluation of IBI305 and Avastin2330-233512Determination of drug-antibody ratio in a cysteine conjugation based antibody-drug conjugate2336-234013Key points for operational steps of vaccine clinical trialsMO Zhao-jun, HUANG Teng, LIANG Xin-yuan2341-234514Establishment and application of a single immunodiffusion method for determining concentration of recombinant Pseudomonas aeruginosa exotoxin A2346-235115Chinese Pharmacopoeia 2015 and the development of bio-pharmaceutical industry in ChinaGUO Zhong-ping2352-235616Recent progress in researches for biomarkers of immunotoxicityGENG Xing-chao, PU Jiang, LI Bo, WANG Jun-zhi2357-236217Impact factors in the process development for therapeutic antibodiesZHU Xiang-yang2363-236818Current progress in the development of human papillomavirus vaccineCHEN Wei-feng, WU Kun-bao, LIAN Zhi-guo, LIU Yu, WU Yan-zhuo, XU Ming-bo2369-2375,240019Advance in development of the drugs targeting EGFR for cancer therapyZHU Hai-you, HU Chang-hua2376-238220Long-term efficacy and safety of tocilizumab in patients with rheumatoid arthritis: an analysis of at least 6 months exposureFENG Xiao-xue, ZHU Shang-ling, CAO Shuang-yan, LIU Fang, GU Jie-ruo, HUANG Jian-lin2383-2387 